Telesis Bio (NASDAQ: TBIO ) stock is on the rise Friday as the synthetic biology company's shares experienced heavy trading this morning. Shares of TBIO stock are off to a strong start on Friday with ...

Telesis Bio, Inc. (NASDAQ:TBIO ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Todd Nelson - Founder, Chief Executive Officer Eric Esser - President, Chief Operating...

Telesis Bio (TBIO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.45 per share a year ago.

Telesis Bio, Inc. (NASDAQ:TBIO ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Jen Carroll - VP, IR Todd Nelson - President, CEO & Director Eric Esser - COO Conferenc...

Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Before the $3.2 billion acquisition of mRNA player Translate Bio Inc (NASDAQ: TBIO) earlier this month, Sanofi SA (NASDAQ: SNY) expressed interest in selling off around 25% of its shares in the compan...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Translate Bio (N...

The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.

The biotech is being bought for $3.2 billion.

Biotech stocks surge after big news & bullish analyst ratings. The post Hot Biotech Stocks To Watch After Sanofi's Acquisition Of Translate Bio appeared first on Penny Stocks to Buy, Picks, News and I...

Sanofi SA (NASDAQ: SNY) has announced it is buying Translate Bio (NASDAQ: TBIO) in a deal valued at about $3.2 billion. These are the details.

A year after paying Translate Bio Inc (NASDAQ: TBIO) a whopping $425 million to develop mRNA vaccines for infectious diseases, including COVID-19, Sanofi SA (NASDAQ: SNY) has announced a $3.2 billion ...

Pfizer, BioNTech and Moderna used mRNA to build effective Covid-19 vaccines in record time, a feat Sanofi is keen to build upon in the future.

Sanofi to acquire U.S.-based Translate Bio in deal valued at $3.2 billion

French drugmaker Sanofi said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio, as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.

PARIS (Reuters) -Sanofi has offered to buy U.S. biotech company Translate Bio, two sources familiar with the situation said on Monday, as the French drugmaker bets on next-generation mRNA technology a...

Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.

Sanofi Pasteur, vaccine unit of Sanofi SA (NASDAQ: SNY) and Translate Bio Inc (NASDAQ: TBIO) have initiated a Phase 1 trial evaluating an mRNA-based investigational vaccine against seasonal influenza....

Translate Bio Inc (NASDAQ: TBIO) has presented positive results from a preclinical study of its mRNA-based therapeutic designed to treat the pulmonary component of primary ciliary dyskinesia (PCD). Mu...